Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of 116.31 million. The enterprise value is 140.34 million.
| Market Cap | 116.31M |
| Enterprise Value | 140.34M |
Important Dates
The next estimated earnings date is Tuesday, October 21, 2025.
| Earnings Date | Oct 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 91.43M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 44.71M |
Valuation Ratios
The trailing PE ratio is 10.31 and the forward PE ratio is 17.17.
| PE Ratio | 10.31 |
| Forward PE | 17.17 |
| PS Ratio | 1.57 |
| PB Ratio | 1.62 |
| P/TBV Ratio | 1.62 |
| P/FCF Ratio | 10.68 |
| P/OCF Ratio | 7.85 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.00, with an EV/FCF ratio of 12.88.
| EV / Earnings | 12.44 |
| EV / Sales | 1.90 |
| EV / EBITDA | 7.00 |
| EV / EBIT | 9.04 |
| EV / FCF | 12.88 |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.48.
| Current Ratio | 2.43 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 1.72 |
| Debt / FCF | 3.17 |
| Interest Coverage | 5.19 |
Financial Efficiency
Return on equity (ROE) is 17.21% and return on invested capital (ROIC) is 9.65%.
| Return on Equity (ROE) | 17.21% |
| Return on Assets (ROA) | 8.37% |
| Return on Invested Capital (ROIC) | 9.65% |
| Return on Capital Employed (ROCE) | 15.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.64 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Cannara Biotech has paid 1.34 million in taxes.
| Income Tax | 1.34M |
| Effective Tax Rate | 10.59% |
Stock Price Statistics
The stock price has increased by +159.81% in the last 52 weeks. The beta is 0.26, so Cannara Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +159.81% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 0.85 |
| Relative Strength Index (RSI) | 45.18 |
| Average Volume (20 Days) | 5,694 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of 74.05 million and earned 11.28 million in profits. Earnings per share was 0.12.
| Revenue | 74.05M |
| Gross Profit | 32.94M |
| Operating Income | 15.53M |
| Pretax Income | 12.62M |
| Net Income | 11.28M |
| EBITDA | 19.85M |
| EBIT | 15.53M |
| Earnings Per Share (EPS) | 0.12 |
Balance Sheet
The company has 10.47 million in cash and 34.51 million in debt, giving a net cash position of -24.04 million.
| Cash & Cash Equivalents | 10.47M |
| Total Debt | 34.51M |
| Net Cash | -24.04M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 71.67M |
| Book Value Per Share | 0.78 |
| Working Capital | 35.90M |
Cash Flow
In the last 12 months, operating cash flow was 14.81 million and capital expenditures -3.92 million, giving a free cash flow of 10.90 million.
| Operating Cash Flow | 14.81M |
| Capital Expenditures | -3.92M |
| Free Cash Flow | 10.90M |
| FCF Per Share | n/a |
Margins
Gross margin is 44.48%, with operating and profit margins of 20.97% and 15.23%.
| Gross Margin | 44.48% |
| Operating Margin | 20.97% |
| Pretax Margin | 17.04% |
| Profit Margin | 15.23% |
| EBITDA Margin | 26.80% |
| EBIT Margin | 20.97% |
| FCF Margin | 14.71% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.64% |
| Shareholder Yield | n/a |
| Earnings Yield | 9.70% |
| FCF Yield | 9.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 2.03 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.03 |
| Piotroski F-Score | 8 |